New RNA combo shows promise in early liver cancer trial
NCT ID NCT05097911
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This early-phase study tests a new RNA-based drug (MTL-CEBPA) together with two immunotherapy drugs (atezolizumab and bevacizumab) in people with advanced liver cancer who have not had prior treatment. The goal is to find the safest dose and see how well the combination shrinks tumors. About 33 adults with liver cancer that has spread or cannot be removed will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore
Conditions
Explore the condition pages connected to this study.